Dasatinib, formerly BMS-354825 or Sprycel®, is a multi-targeted kinase inhibitor that is not restricted to SFKs but also targets, e.g., the tyrosine kinase BCR-ABL1 (Lombardo et al., 2004), and is generally used as drug in leukemia therapy. This evidence concerns the gene BCR and leukemia.